Define the strain, CFU time point and package before calling a gummy “probiotic.”
Sucotond USA coordinates non-confidential feasibility review for U.S. brands planning custom probiotic gummies. The review connects organism identity, viable-count claim, process exposure, method, package, storage and time-point evidence before a commercial commitment.
This is a custom-project service page, not a claim that one stocked formula, strain, CFU amount, process, test method or shelf life fits every project.
Project Starting PointA microorganism name is not a complete product specification
A reviewable brief distinguishes the exact organism from the viable-count statement, the conditions it encounters during manufacturing and storage, and the evidence used to accept the finished product.
Strain identity
Genus and species alone may not identify the material used in supporting records. Capture the strain designation, supplier, form, identity basis and applicable safety pathway.
CFU claim basis
State the amount, serving and time point. A count at manufacture is not automatically the count at release, purchase or the proposed end of shelf life.
Process and matrix
Material form, addition stage, temperature, water activity, co-ingredients and hold conditions can make one production pathway different from another.
Package and storage
Container, closure, moisture exposure, storage statement and distribution assumptions belong to the viability evidence—not only to the packaging quote.
Eight decisions that make a probiotic gummy project reviewable
1. Organism and material identity
- Genus, species and strain designation
- Supplier, material form and carrier
- Identity method and reference documentation
- Applicable history-of-use, safety or NDI review owner
2. Viable-count label target
- Target CFU per serving and acceptable piece count
- Whether the value refers to manufacture, release or a later time point
- Weight declaration and voluntary CFU wording reviewed together
- Exact label and claim approval responsibility
3. Manufacturing exposure
- Proposed addition stage and material handling
- Relevant temperature, moisture and hold-time questions
- Mixing and sampling assumptions
- Differences between development sample and commercial line
4. Gummy and co-ingredient system
- Gelling and sweetener system requirements
- Acid, flavor, color, coating and other actives
- Prebiotic or other combination concepts kept distinct
- Formula changes that trigger renewed compatibility review
5. Enumeration and identity methods
- Method/reference and intended use
- What the method counts and what it does not distinguish
- Sample preparation and gummy-matrix suitability
- Laboratory, units, reporting rules and result limitations
6. Packaging and storage
- Container, closure, count and moisture-control assumptions
- Storage statement and distribution conditions
- Package-change and label-revision controls
- Evidence linked to the commercial configuration
7. Time-point and trend plan
- Baseline and applicable release measurement
- Proposed time points and acceptance criteria
- Formula/package/batch coverage
- Trend, excursion, retest and shelf-life decision owners
8. Commercial and document scope
- Target market, volume stage and delivery point
- Required component, batch, laboratory and stability records
- Disclosure and publication rights
- MOQ, timing and quote validity confirmed after review
Build a probiotic gummy evidence-plan brief
Organize five buyer-controlled decisions before requesting a strain, formula or commercial commitment. The result identifies an evidence-planning path and open gates; it is not strain approval, a CFU result, shelf-life support or a manufacturing verdict, and it is not a commercial commitment.
First evidence-planning path
Open buyer decisions
Minimum evidence gates
Boundary: This browser-only brief organizes buyer inputs. It does not establish strain identity, safety or NDI status, label compliance, viable count, method suitability, manufacturability, shelf life, efficacy or commercial terms.
Request a Non-Confidential ReviewSelections and copied results stay in this browser and are not submitted with the inquiry form. Privacy-limited measurement may record only that the tool was used; it contains no selections, result or persistent identity. Privacy notice.
Make every probiotic field carry its own evidence question
The table is intentionally not prefilled with a strain, CFU amount or shelf life. Those values become publishable only when they belong to the approved project and evidence scope.
| Project field | Buyer input | Required confirmation before commitment |
|---|---|---|
| Microbial material | Exact strain or acceptable strain/material criteria | Supplier, identity, form, carrier, component specification and applicable safety path |
| CFU declaration | Amount, serving and proposed claim time point | Label basis, units, method, acceptance criteria and evidence time point |
| Finished formula | Gummy system, co-ingredients, exclusions and sensory direction | Approved composition, process, ingredient list and change triggers |
| Process exposure | Known material limitations and desired manufacturing path | Addition stage, handling, mixing, sampling and commercial-scale verification |
| Test method | Enumeration and identity evidence expected | Method suitability, sample preparation, laboratory scope, units and limitations |
| Package and storage | Container, closure, count, storage wording and route | Commercial package, protective assumptions, label revision and distribution scope |
| Time-point support | Proposed shelf-life date and acceptance basis | Formula, package, conditions, batches, time points, trend and quality decision |
| Commercial terms | Volume stage, market, delivery point and launch window | Materials, package, evidence scope, quantity, timing and current quote |
Connect the received strain to the labeled commercial lot
Material
Strain, supplier, identity, lot, form and component criteria.
Formula
Serving, co-ingredients, intended label, package and approved revision.
Process
Addition, handling, exposure, mixing, sampling and controlled records.
Finished batch
Identity, enumeration, other specifications and quality disposition.
Time points
Formula/package/conditions/batches, results, trends and deviations.
Label release
Effective CFU wording, storage, count, artwork and distributed-lot link.
Use the product specification checklist to define acceptance fields, the laboratory report checklist to review method and result scope, the shelf-life evidence checklist to connect time points, and the label/artwork checklist to control the final claim revision.
FDA's CFU document is a draft guidance—not a final CFU-only rule
FDA's 2018 document is labeled Draft—Not for Implementation and contains non-binding recommendations. It describes proposed enforcement discretion for declaring live microbial quantity in colony-forming units in addition to the quantitative amount by weight required by regulation, when the stated conditions are met. A project file should therefore preserve the exact label basis and current regulatory review rather than reducing the issue to “CFU is allowed.”
Government information supports two buyer questions—not a product claim
Which exact strain?
NIH's Office of Dietary Supplements explains that probiotic organisms are identified by genus, species and strain and that effects can vary by strain. Its fact sheet also distinguishes viable CFU amounts and notes that counts can decline over time. That supports a buyer requirement to identify the strain and CFU time point; it does not establish the efficacy of an unreviewed gummy.
Does the ingredient require an NDI assessment?
FDA's revised 2024 NDI guidance is also a draft and not for implementation. For a live microbial dietary ingredient, it recommends a complete organism and strain description, identity methods and a relationship to the strain used for history-of-use or other safety evidence. The responsible firm should determine the actual notification path for the specific ingredient and conditions of use.
The label claim still needs a controlled manufacturing and quality file
FDA's dietary-supplement CGMP guide describes component identity and specifications, in-process controls, finished-product specifications, appropriate scientifically valid tests or examinations, packaging and label specifications, master/batch records and quality-control disposition. For a live microbial project, those controls must connect to the selected organism and the decision being made.
- Component: identify the received material and establish relevant specifications rather than relying on a marketing name.
- Process: define the production controls and records needed to connect the material to an identified batch.
- Method: state what is enumerated, the sample and units, method suitability and result limitations.
- Finished product: establish the applicable identity, strength/composition and contaminant criteria and quality disposition.
- Package and label: reconcile the effective CFU statement, storage wording, package configuration and time-point support.
FDA Dietary Supplement CGMP Small Entity Compliance Guide
Keep sales, manufacturing, brand and evidence roles visible
Brooklyn project office
Sucotond USA coordinates non-confidential buyer inputs, commercial communication, evidence requests, project status and delivery planning. It does not select a strain or approve a health claim on the brand's behalf.
Guangzhou production facility
The company identifies Sucotond (Guangzhou) Health Biotechnology Co., Ltd. as responsible for development, feasibility, production, in-process controls and batch records. Facility evidence and product evidence remain separate.
Brand / responsible firm
The brand defines the intended market, organism and claim basis, approves the formula/specification and obtains qualified safety, NDI, labeling and substantiation review for its product.
Supplier and laboratory
The supplier and laboratory records must be matched to the exact strain, material lot, sample, method and report. Their existence does not automatically authorize public use or validate a different batch.
Probiotic gummy project questions
What strain information is needed for a probiotic gummy project?
Identify the genus, species and strain designation, supplier and material form, applicable identity and safety documentation, intended amount and label wording. If the strain is not yet selected, state the acceptable categories and the evidence the brand requires before approval.
Is the CFU amount at manufacture the same as the amount through shelf life?
Not necessarily. Viable counts can change during processing and storage. A project should state the CFU claim basis and time point, storage and package assumptions, applicable method, sampling plan and acceptance criteria instead of treating an initial count as an end-of-shelf-life result.
Does Sucotond USA offer a stocked probiotic gummy formula?
This page offers a custom-project feasibility review, not a representation that one universal stocked formula is suitable for every strain or brand. The organism, label basis, process, co-ingredients, test method, package, storage and commercial terms require project-specific confirmation.
Can one published probiotic gummy study validate a different product?
No. A study belongs to its identified strain, material, formula, process, serving, package, storage conditions, method and study design. Its findings cannot be assigned to another strain or finished gummy without corresponding evidence and regulatory review.
What evidence can a brand request for a commercial probiotic gummy project?
Define the applicable strain identity and component records, approved formula and product specification, process-exposure review, sample approval, master and batch records, agreed enumeration reports, package and label revision, stability time points and quality disposition. Availability and disclosure rights depend on the project and document owners.
Request a probiotic gummy feasibility map
Share the organism status, proposed CFU label basis, serving, gummy system, package, storage, market, volume stage and timing. The review identifies open questions; it is not a formula, quote, method, result or production commitment.
Brooklyn, NY 11214